March 22, 2022
Life Sciences
  • The Food and Drug Administration (FDA) is ramping up in-person inspections of drug and device manufacturing facilities that were delayed during the pandemic. The FDA said it plans to return to a “normal cadence” next month for inspections overseas, where roughly 3 in 4 facilities making active drug ingredients for the U.S. market are located. The agency typically inspects about 12,500 U.S. facilities and 3,100 facilities abroad annually, but in 2021 those numbers fell to about 6,100 and 167, respectively. (Article here)